Scholarlink

Introduction <p>In wild-type transthyretin amyloidosis (ATTRwt), the deposition of transthyretin in the myocardium leads to progressive heart failure. However, little is known about the short-term natural progression of this disease and potential predictors of outcome.</p> Objectives &amp; methods <p>Therefore, this study longitudinally analyzed the clinical findings (ECG, echocardiography, and laboratory tests) of 65 patients suffering from ATTRwt at baseline and at follow-up visits after 12 months.</p> Results <p>In total, 44 patients (67.7%) presented with abnormal ECGs, prolonged PR and QRS durations and low-voltage patterns. Pacemaker placement was performed in eleven patients (16.9%). At the one-year follow-up visit, we detected significant increases in the QRS duration (from 119.7 ± 4.0 to 125.9 ± 4.3 ms; <i>p</i> &lt; 0.05), intraventricular septum thickness (from 18.9 ± 0.5 mm to 19.9 ± 0.5 mm; <i>p</i> &lt; 0.05) and ejection fraction (EF) (from 45.4 ± 2.1% to 38.9 ± 2.6%; <i>p</i> &lt; 0.05) compared with those at the baseline visit. During follow-up, 16 patients (24.6%) died. Predictors of worse outcomes were progression in QRS duration, low EF, reduced renal function, impaired right ventricular function and the need for pacemaker implantation.</p> Conclusions <p>In ATTRwt, precise evaluation via routine cardiac diagnosis helps to identify patients with an elevated risk of mortality. Patients with prolonged QRS duration, progressive myocardial hypertrophy, right ventricular failure, reduced renal function and the need for cardiac pacemakers are at increased risk for one-year mortality.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Progression of QRS duration – a potential surrogate marker of survival in ATTRwt amyloidosis patients

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月20日

查看全文
  • Selina Hein,
  • Fabian aus dem Siepen,
  • Sonja M. Zierleyn,
  • Maximilian Knoll,
  • Hugo A. Katus,
  • Norbert Frey,
  • Arnt V. Kristen

摘要

Introduction

In wild-type transthyretin amyloidosis (ATTRwt), the deposition of transthyretin in the myocardium leads to progressive heart failure. However, little is known about the short-term natural progression of this disease and potential predictors of outcome.

Objectives & methods

Therefore, this study longitudinally analyzed the clinical findings (ECG, echocardiography, and laboratory tests) of 65 patients suffering from ATTRwt at baseline and at follow-up visits after 12 months.

Results

In total, 44 patients (67.7%) presented with abnormal ECGs, prolonged PR and QRS durations and low-voltage patterns. Pacemaker placement was performed in eleven patients (16.9%). At the one-year follow-up visit, we detected significant increases in the QRS duration (from 119.7 ± 4.0 to 125.9 ± 4.3 ms; p < 0.05), intraventricular septum thickness (from 18.9 ± 0.5 mm to 19.9 ± 0.5 mm; p < 0.05) and ejection fraction (EF) (from 45.4 ± 2.1% to 38.9 ± 2.6%; p < 0.05) compared with those at the baseline visit. During follow-up, 16 patients (24.6%) died. Predictors of worse outcomes were progression in QRS duration, low EF, reduced renal function, impaired right ventricular function and the need for pacemaker implantation.

Conclusions

In ATTRwt, precise evaluation via routine cardiac diagnosis helps to identify patients with an elevated risk of mortality. Patients with prolonged QRS duration, progressive myocardial hypertrophy, right ventricular failure, reduced renal function and the need for cardiac pacemakers are at increased risk for one-year mortality.